The 2026 Bispecific Antibody Drug Discovery Report

https://www.wuxibiologics.com/cro-services/resources/papers-posters/bispecific-antibody-report/?utm_campaign=49846937-2026%20Bispecific%20Antibody%20Drug%20Discovery%20Report&utm_source=DDN&utm_medium=Featured%20Ad&utm_content=DDN%20Newsletter%20Feature%20Top%20Ad%20%3A%202026%20Bispecific%20Antibody%20Drug%20Discovery%20Report What does it take to build a successful bispecific antibody program? The 2026 Bispecific Antibody Drug Discovery Report brings together perspectives from WuXi Biologics technical leaders, scientific advisors, and scientists, many with 10-25+ years of biologics drug discovery experience. Their expertise spans molecular design, engineering, production, early developability assessment, functional evaluation, and platform innovation across diverse biologics programs. These technical perspectives are complemented by strategic insights from our experience as a global CRDMO, along with curated tracking of the bsAb landscape since 2025.